31 – 40 of 69
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2012
-
Mark
Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
(
- Contribution to journal › Article
-
Mark
The hyperstimulated beta-cell: prelude to diabetes?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Using albumin to improve the therapeutic properties of diabetes treatments.
(
- Contribution to journal › Article
-
Mark
Pancreatic β-cell dysfunction, expression of iNOS and the effect of phosphodiesterase inhibitors in human pancreatic islets of type 2 diabetes.
(
- Contribution to journal › Article
- 2011
-
Mark
Editorial: Long in the shade, glucagon re-occupies centre court
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mechanisms of Action of the DPP-4 Inhibitor Vildagliptin in Man.
(
- Contribution to journal › Scientific review
-
Mark
Gastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase 4 activity in obese patients with type 2 diabetes.
(
- Contribution to journal › Article
-
Mark
Can sulphonylurea addition to lifestyle changes help to delay diabetes development in subjects with impaired fasting glucose? The Nepi ANtidiabetes StudY (NANSY)
(
- Contribution to journal › Article
-
Mark
Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
(
- Contribution to journal › Article
-
Mark
The future of incretin-based therapy: novel avenues-novel targets.
(
- Contribution to journal › Article